Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
Clinical trial NCT03960541 · TERMINATED
Trial details
- NCT number
- NCT03960541
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-31
- Primary completion
- 2021-05-27
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.